Dr. Mary Claire Haver on Women's HRT: What Clinicians Should Tell Patients

Who Is Dr. Mary Claire Haver and Why Do Clinicians Need to Know Her?

Dr. Mary Claire Haver is a board-certified OB/GYN based in Texas whose clinical practice focuses on menopause management and metabolic health in midlife women. She founded The Pause Life, an online platform that combines telehealth HRT prescribing with nutrition and lifestyle programming. Her 2022 book "The Menopause Diet Plan" and 2024 book "The New Menopause" reached bestseller status, and her TikTok and Instagram accounts have collectively accumulated more than five million followers.

That reach is the clinical issue.

Why Her Platform Changes the Patient Encounter

Patients are arriving at primary care offices, gynecology practices, and telehealth consults having already watched dozens of her videos. They know the difference between conjugated equine estrogen and estradiol. They are asking about transdermal delivery to minimize first-pass hepatic metabolism. Some are arriving with printed lab panels requesting FSH, estradiol, and testosterone levels.

A 2023 survey published in Menopause (the journal of the Menopause Society) found that 74% of women aged 45 to 60 had sought menopause information from social media before speaking to a clinician [1]. Haver is among the most-cited voices in that space. Clinicians who dismiss her messaging risk damaging therapeutic alliance; those who understand it can channel patient motivation productively.

Her Credentials Matter for the Conversation

Haver trained in obstetrics and gynecology and holds a culinary medicine certification from Tulane University. She is not a fringe voice. Her public statements are, in most areas, consistent with the positions of the Menopause Society, the American College of Obstetricians and Gynecologists (ACOG), and the Endocrine Society. Knowing that helps clinicians contextualize her advice for patients who ask "Is what she says real?"

What Does Dr. Mary Claire Haver Actually Take? Her Disclosed HRT Regimen

Haver has been direct in multiple podcast interviews and social media posts about her personal hormone therapy regimen. She is perimenopausal and has disclosed using transdermal estradiol combined with oral micronized progesterone (Prometrium). She has also mentioned using testosterone, typically compounded, for libido and energy, a use that remains off-label in the United States for women.

The Specific Agents She Has Named

In a 2023 appearance on the Huberman Lab podcast, Haver described her own use of:

• Transdermal estradiol (patch or gel form, exact dose not publicly specified)
• Oral micronized progesterone 100 mg nightly (for women with a uterus, to protect the endometrium)
• Low-dose compounded testosterone (dose not publicly specified)

She has explicitly stated she chose transdermal estradiol over oral conjugated equine estrogen because transdermal delivery does not increase hepatic synthesis of clotting factors, a point directly supported by pharmacokinetic data [2].

What the Evidence Says About Her Chosen Agents

Transdermal estradiol avoids the first-pass hepatic effect associated with oral estrogens. A 2010 case-control study published in BMJ (the ESTHER study, N=881 cases) found that oral estrogen was associated with a fourfold increased risk of venous thromboembolism compared to non-use, while transdermal estradiol was not associated with a significantly elevated risk [3]. That finding has since been supported by meta-analytic data.

Oral micronized progesterone appears to carry a more favorable breast-risk profile than synthetic progestins. The E3N cohort study (N=80,377 French women, followed up to 8.9 years) found that use of estradiol combined with micronized progesterone was not associated with a statistically significant increase in breast cancer risk, while estrogen plus synthetic progestins was [4]. Haver cites this distinction frequently, and it is one clinicians should be prepared to discuss.

Her Core Clinical Positions and How They Align With Guidelines

Understanding Haver's publicly stated clinical positions allows clinicians to either reinforce accurate information or gently correct areas where evidence is still evolving.

The Timing Hypothesis (Window of Opportunity)

Haver consistently emphasizes beginning hormone therapy close to the onset of menopause rather than waiting years. This is the "timing hypothesis," and it has substantial trial support.

The ELITE trial (Early versus Late Intervention Trial with Estradiol, N=643) found that estradiol slowed the progression of subclinical atherosclerosis (measured by carotid intima-media thickness) only when therapy began within six years of menopause onset. Women who started more than ten years post-menopause did not experience the same cardiovascular benefit [5]. The KRONOS Early Estrogen Prevention Study (KEEPS, N=727) similarly showed no adverse cardiovascular effect of hormone therapy initiated in recently menopausal women [6].

The 2022 Menopause Society position statement states: "For women who are aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture" [7].

Haver's public messaging closely mirrors that language.

The WHI Misinterpretation Problem

Haver spends considerable time correcting what she calls the "WHI hangover," the clinical overcorrection that followed the 2002 Women's Health Initiative results. She is accurate that the original WHI findings have been substantially recontextualized.

The original WHI arm that was halted in 2002 used conjugated equine estrogen plus medroxyprogesterone acetate in women with a mean age of 63, many of whom were obese or had pre-existing cardiovascular disease. A 2013 reanalysis by Manson et al. In JAMA (N=27,347 across both WHI arms) found that women aged 50 to 59 at enrollment who used estrogen-only therapy had lower all-cause mortality and lower coronary heart disease rates than placebo [8]. The subgroup most relevant to typical hormone therapy candidates did not show net harm.

Clinicians can tell patients: "Dr. Haver is right that the original WHI population was older and sicker than most women seeking HRT today. The reanalyses support a more nuanced conversation."

Testosterone for Women: Where She Goes Off-Label

Haver advocates for testosterone therapy in women experiencing low libido, fatigue, and cognitive symptoms. She uses compounded low-dose testosterone for herself and recommends it clinically. This deserves honest discussion with patients.

The Endocrine Society's 2019 clinical practice guideline on androgen therapy in women states that testosterone therapy is appropriate for hypoactive sexual desire disorder (HSDD) in postmenopausal women, based on randomized trial data, but notes that no testosterone product is currently FDA-approved for women in the United States [9]. Compounded testosterone is used off-label. Dose, monitoring, and long-term safety data are more limited than for estradiol.

Clinicians should acknowledge the evidence base for libido improvement while being transparent about the regulatory status and the need for periodic monitoring of total testosterone levels to avoid supraphysiologic dosing.

What the Symptom Data Says: Why Patients Are Motivated

Haver's patient base is not abstract. The symptom burden driving women to seek her content is real and measurable.

Vasomotor Symptoms

Up to 80% of menopausal women experience vasomotor symptoms (hot flashes and night sweats), and approximately 25% describe them as severe [10]. The SWAN (Study of Women's Health Across the Nation) cohort showed that median duration of moderate-to-severe vasomotor symptoms is 7.4 years, with Black women experiencing symptoms for a median of 10.1 years [11]. That duration is not trivial.

Estradiol therapy remains the most effective pharmacologic treatment for vasomotor symptoms. A Cochrane review of 24 randomized trials found that estrogen reduced hot flash frequency by approximately 75% compared to placebo [12].

Sleep, Mood, and Cognitive Symptoms

Haver frequently discusses sleep disruption, anxiety, and brain fog as underrecognized menopause symptoms. She is supported by data. The SWAN cohort found sleep disturbance to be significantly associated with perimenopause transition independent of vasomotor symptoms [11]. Randomized trial evidence for estradiol's effect on depressive symptoms in perimenopause (not established menopause) is also favorable, as reviewed in a 2018 JAMA Psychiatry meta-analysis [13].

The Clinician's Practical Communication Framework

Clinicians seeing patients influenced by Haver's content benefit from a consistent conversation structure. The framework below is based on Menopause Society guidance and the evidence cited in this article.

Step 1. Validate, Then Verify

Open with: "A lot of what Dr. Haver describes reflects real evidence. Let me show you where her recommendations fit the guidelines and where some details are still being studied."

This preserves trust and positions the clinician as a partner rather than a gatekeeper.

Step 2. Establish the Risk Profile First

Before any prescribing conversation, assess:

• Personal and family history of VTE, stroke, or breast cancer (particularly hormone receptor-positive)
• Cardiovascular risk factors (hypertension, dyslipidemia, smoking history, diabetes)
• Time since menopause onset (the timing hypothesis is clinically significant)
• Uterine status (intact uterus requires progestogen co-administration)
• Current symptom burden using a validated tool such as the Menopause Rating Scale or the Greene Climacteric Scale

Step 3. Route and Agent Selection Is Not One-Size

For most low-risk women under 60 or within ten years of menopause, transdermal estradiol plus oral micronized progesterone (if uterus intact) is a reasonable first choice based on the VTE and breast cancer data described above. Standard starting doses are estradiol 0.025 to 0.05 mg/day transdermal with oral micronized progesterone 100 mg nightly [7].

Step 4. Set Expectations on Timeline and Monitoring

Most women see vasomotor improvement within four to eight weeks. A follow-up visit at 12 weeks allows dose adjustment. Annual review of continued need, symptom status, and any new risk factors is consistent with Menopause Society guidance. Lab monitoring (estradiol levels, lipid panel) at three to six months is reasonable practice at many centers, though the Menopause Society does not mandate specific serum estradiol targets.

Step 5. Address Testosterone Separately

If the patient raises testosterone (and, increasingly, they will), use this framing: "There is good evidence for testosterone in women with hypoactive sexual desire disorder. It is off-label in the U.S., so we would use a compounded product, start low, and check your levels at three months to stay in a physiologic range."

Where Haver's Messaging Has Clinical Nuance That Warrants Discussion

Breast Cancer Risk Communication

Haver acknowledges breast cancer risk but argues it has been overstated relative to the benefits for symptomatic women. The absolute risk numbers support measured nuance. In the Million Women Study, the excess risk associated with combined HRT was approximately 6 additional cases per 1,000 women over 10 years of use [14]. That is a real but modest absolute risk, and it must be weighed against quality-of-life benefits, fracture prevention, and cardiovascular data in younger menopausal women.

The ACOG Practice Bulletin No. 141 states that "for healthy, symptomatic women younger than 60 who are within 10 years of menopause, hormone therapy is appropriate when there are no contraindications" [15]. Clinicians can share that framing directly.

Compounded vs. FDA-Approved Products

Haver uses and recommends compounded bioidentical hormones, and she is transparent that the "bioidentical" marketing term is not itself a regulatory category. FDA-approved estradiol products (patches such as Vivelle-Dot, Climara; gels such as Divigel, EstroGel; and oral micronized progesterone Prometrium) are bioidentical in chemical structure. Compounding is appropriate when a specific dose or delivery route is not available commercially, but compounded products are not subject to the same manufacturing quality controls as FDA-approved products. Clinicians should note this distinction without dismissing compounding as inherently inferior.

Practical Takeaways for the 15-Minute Office Visit

Patients asking about Haver's recommendations rarely need a 45-minute education session. A structured short visit works.

• Confirm the patient has had menopause confirmed or perimenopause established clinically.
• Use a brief validated symptom scale. The 10-item Menopause Rating Scale takes under two minutes.
• Screen for contraindications in under five minutes using ACOG's checklist.
• If appropriate, initiate transdermal estradiol 0.05 mg/day plus oral micronized progesterone 100 mg nightly.
• Schedule a 12-week follow-up.
• Document that the prescribing decision was individualized and consistent with current Menopause Society guidance.

Women with contraindications to estrogen (active or history of estrogen receptor-positive breast cancer, unexplained vaginal bleeding, active liver disease, prior VTE or stroke) have non-hormonal options. Fezolinetant (Veozah), an FDA-approved neurokinin 3 receptor antagonist, reduced hot flash frequency by 63% versus placebo at 12 weeks in the SKYLIGHT 1 trial (N=501) [16]. SSRIs and SNRIs (particularly paroxetine 7.5 mg, the only FDA-approved non-hormonal option at the time of writing before fezolinetant's 2023 approval) are also discussed in ACOG guidance [15].